{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"367","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Response is assessed throughout the 1 year post treatment timeframe. Morphologic criteria for response:\n\nComplete Response (CR) = Bone Marrow blasts \\<5%; no blasts with Auer rods; no extramedullary disease. Transfusion independent.\n\nPlatelets ≥ 100,000/μl Absolute neutrophil count \\>1000/μl (CRi: incomplete hematologic recovery CRp: incomplete platelet recovery)\n\nPartial Response (PR) = Decrease of at least 50% in the percentage of blasts to 5-25% in the bone marrow and the normalization of blood counts as for CR. (PRi and PRp if incomplete hematologic or platelet recovery)\n\nStable Disease (SD) = Failure to achieve at least PR, but no evidence of progression for \\>4 weeks.","dispersionType":"Full Range","groups":[{"description":"Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.","id":"OG000","title":"Group 2 (Avelumab, MHC Class I Up-regulation, T Cells)"}],"paramType":"MEDIAN","populationDescription":"4 patients in Arm II did not relapse and were not assessed. 1 pt progressed at their D365 visit timepoint which landed on D367. They were included in the count of participants that passed within their 1 year follow-up timeframe.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Anti-leukemic Potential Efficacy, in Terms of Duration of Response (Arm II)","type":"PRIMARY","unitOfMeasure":"days"}